Increased Need for Improvement in the Treatment of Non-Luminal A Subtype Metastatic Breast Cancer in First-Line Treatment

The DBCG 25R-DISCORDANT trial is a Danish study focusing on treatment options for metastatic breast cancer, specifically targeting non-Luminal A, ER-positive/HER2-low PAM50 subtype with a good performance status. The trial aims to compare trastuzumab deruxtecan with CDK4/6 inhibitors, assessing progression-free survival and other key outcomes. Almost all oncology departments in Denmark are participating in the study, and the Nordic oncology community is also invited to take part.